Resolve Therapeutics, a Seattle, WA-based biotechnology company, has raised $5.8m in Series B financing.
The round was led by existing investor New Science Ventures, with participation of new investor WRF Capital and previous investor Easton Capital.
The company intends to use the capital to advance their investigational lupus compound RSLV-132 into clinical trials, which we expect to start in mid-2013.
Led by CEDO James Posada, Ph.D., Resolve Therapeutics focuses on lupus. RSLV-132 represents a new approach to inhibiting the production of interferon-alpha at a proximal step in the inflammatory cascade.
FinSMEs
01/11/2012